ASCO, the largest event in cancer research, is approaching on May 31st. This year's meeting promises to be particularly groundbreaking, with new findings and innovations that could revolutionize cancer treatment.
The U.S. Food and Drug Administration recently approved two new wound management products that include patented hydrogels invented by University of Delaware researchers. The unique UD hydrogel materials self-assemble to form a 3D matrix compatible with living cells.
Location, race and insurance status play a significant part in the odds of a patient being diagnosed with early-stage or late-stage cancer, according to a detailed medical records analysis of more than 94,000 patients with cancer by researchers at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center.
Lucy, with her boundless puppy-like energy even at 12 years old, is more than just a pet to Susan Ketcham. She's now part of a research project that could transform the way we treat brain cancer – in both dogs and humans. This study at Virginia Tech's Virginia-Maryland College of Veterinary Medicine explores an innovative therapy called histotripsy.
The number of mutations in the DNA of cancerous tumors may not be an indicator of how well patients will respond to immune checkpoint inhibitors (ICIs), a commonly prescribed type of immunotherapy, a team led by UT Southwestern Medical Center researchers reported in a retrospective study. The findings, published in Nature Cancer, upend long-held conventional wisdom and could lead to more effective ways of deciding which patients will benefit most from this type of treatment.
A team of researchers led by Associate Professor Alfredo Franco-Obregón from the NUS Institute for Health Innovation & Technology (iHealthtech) has unveiled a novel approach to stimulate muscle, by way of using brief and mild pulsed electromagnetic field exposure, to produce and release proteins possessing anticancer properties.
An FDA committee voted unanimously last month to approve a new clinical endpoint, minimal residual disease, when evaluating proposed drugs to treat multiple myeloma. The 12-0 vote was based primarily on an analysis spearheaded by C. Ola Landgren, M.D., Ph.D., first author of a new paper published May 20 in the journal Blood.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
May is Skin Cancer Awareness month, intended to call attention to the most common, but also most preventable, form of cancer. With summer just around the corner, Dr. Stephanie Lareau with the Virginia Tech Carilion School of Medicine outlined many ways to protect yourself from too much ultraviolet radiation and avoid the dangers of too much sun exposure.
When it comes to skin cancer, most people think of warnings about sunburn and tanning beds. Thoughts of “cancer genes” or inherited risks are reserved for diseases like breast cancer or colon cancer. A new study challenges this status quo by showing that genetics play a larger role in melanoma risk than recognized. Physicians rarely order genetic screens to assess risk factors for patients with a family history of melanoma because, according to the previous, limited studies, only 2-2.5% of all cases are genetic. For the same reason, insurance companies rarely cover these tests outside of the most extreme situations. In the medical field, genetic testing is generally not offered for cancers that don’t meet a threshold of 5%. A study from researchers and clinicians led by Cleveland Clinic’s Joshua Arbesman, MD, and Stanford Medicine’s Pauline Funchain, MD (formerly Cleveland Clinic), suggests that melanoma more than meets that threshold.
Researchers at UT Southwestern Medical Center have developed a novel artificial intelligence (AI) model to improve the detection of breast cancer metastasis, which could reduce the need for needle or surgical biopsies.
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.
Researchers at Sinai Hospital of Baltimore have found a possible relationship between receiving chemotherapy within a year of total joint replacement surgery and increased incidence of infection in the replaced joint. Findings published this month in the Archives of Orthopaedic and Trauma Surgery.
Skin Brachytherapy, also called radiation seed therapy, offers a non-invasive radiation therapy solution to complement or replace surgery for certain skin cancers. Rajesh V. Iyer, MD, is a radiation oncologist at RWJBarnabas Health and chairman of radiation oncology at Community Medical Center, shares more about this treatment option for patients.
Researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil, a cognitive-enhancing medicine used in the treatment of Alzheimer’s disease. The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.
Grateful Patient Returns to Hackensack University Medical Center to Motivate Patients & Team Members During National Hospital Week 2024
The National Comprehensive Cancer Network participates in meetings hosted by Maria Sklodowska-Curie National Research Institute of Oncology, the Polish Oncological Society, and Alliance for Innovation to advance work adapting proven cancer treatment guidelines for Poland.
Hearst Health and the UCLA Center for SMART Health today announced that a panel of expert judges has selected Mount Sinai Health System and The University of Texas MD Anderson Cancer Center as the 2024 Hearst Health Prize finalists. The winner will be announced at UCLA Health Data Day on June 4, 2024.
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced it is in advanced discussions with Memorial Sloan Kettering Cancer Center (MSK) to initiate a preclinical study evaluating MIRA's novel oral ketamine analog, Ketamir-2, for the treatment of cancer-related pain and depression.
Showing results
1–20 of 24808
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
